PofoliaPofolia ile paylaşıldı

Cartilage· 2026Q1

Bileşik Kırık Sıvısı Hematomuna Ardışık Maruz Kalma, Ayak Bileği Kırığı Sonrası İn Vitro Kıkırdak Hasarını Teşvik Eder ve Kısmen Anti-inflamatuar Ajanlarla Azaltılır

Sequential Exposure to Acute, Intermediate, and Late Synovial Fluid Fracture Hematoma after Ankle Fracture Promotes Cartilage Damage in Vitro Partially Attenuated by Anti Inflammatory Agents

Evan Fedock, Nicholas B. Allen, Alexandra Hunter Aitchison, Will Sharp ve diğerleri

Kısa özet

Ayak bileği kırıklarından elde edilen sinoviyal sıvı kırık hematomuna (SFFH) ardışık maruz kalma, in vitro ortamda kıkırdak dejenerasyonunu teşvik etti; anti-inflamatuar ajanlar (IL-1Ra, deksametazon, doksisiklin) inflamatuar sitokinleri ve MMP'leri azalttı ancak kıkırdak matriks dejenerasyon belirteçlerinin yüksekliğini veya histolojik korumayı önemli ölçüde iyileştirmedi.

Yapay zekâ ile başlık ve abstract'tan üretildi; tam metin okunmaz.

Ana noktalar

  • SFFH'nin in vitro ortamda ardışık maruz kalması, pro-inflamatuar sitokinleri, MMP'leri ve kıkırdak yıkım ürünlerini artırdı.
  • Anti-inflamatuar ajanlar (IL-1Ra, deksametazon, doksisiklin), kültürlenmiş kıkırdaktaki inflamatuar sitokinleri ve MMP seviyelerini azalttı.
  • İnflamasyondaki azalmaya rağmen, kıkırdak matriks dejenerasyon belirteçleri (CTX-II, sGAGs) yüksek kaldı ve histolojik koruma önemli ölçüde iyileşmedi.
  • Test edilen gruplar arasında kondrosit sağkalımında önemli bir fark gözlenmedi.

Yapay zekâ ile başlık ve abstract'tan üretildi; tam metin okunmaz.

Özet (abstract)

Background Post-traumatic osteoarthritis (PTOA) following intra-articular fractures (IAFs) remains a common sequela after injury. Cartilage degeneration after injury is influenced by multiple factors, including elevated proinflammatory cytokines produced by synovial fluid fracture hematoma (SFFH). Targeting this inflammatory response may reduce cartilage damage. This study evaluated cartilage injury and inflammatory mediator changes caused by SFFH, assessing whether commercially available anti-inflammatory agents can suppress the inflammatory cascade implicated in PTOA and reduce chondrocyte death. Methods Ankle synovial fluid was collected from 54 patients with IAFs. Human cartilage discs harvested from talar allografts were cultured in standard chondrocyte media (SCM) and initial media was collected. Explants were randomized into five groups: (1) control (SCM only), (2) sequential exposure SFFH representing acute (days 0–2), intermediate (days 3–9), and late (≥10) phases, (3) Group 2 with interleukin-1 receptor antagonist (IL-1Ra), (4) Group 2 with dexamethasone, and (5) Group 2 with doxycycline. After exposure, spent media was collected. Samples were analyzed for cytokines, matrix metalloproteinases (MMPs), C-terminal telopeptides of type II collagen (CTX-II), and sulfated glycosaminoglycans (sGAGs), with histological assessment performed to evaluate viability and proteoglycan content. Results SFFH exposed cartilage showed increased levels of proinflammatory cytokines, MMPs, and cartilage breakdown products compared to controls. Treatment with IL-1Ra, dexamethasone, or doxycycline all reduced inflammatory cytokines and MMP levels. Safranin O staining, indicating proteoglycan content, was lowest in group 2. No significant difference in chondrocyte survival was observed among groups. Conclusion Sequential exposure to SFFH creates a sustained proinflammatory and catabolic environment that promotes biochemical cartilage degradation. IL-1Ra, dexamethasone, and doxycycline reduced inflammatory cytokine and MMP concentrations while cartilage matrix degradation markers remained elevated and histologic preservation was not significantly improved. These findings suggest that suppression of inflammatory pathways alone may be insufficient to fully prevent cartilage injury under cumulative SFFH exposure. Clinical Relevance Acute anti-inflammatory therapy following IAF may modulate inflammatory and catabolic mediator production within the post-fracture joint environment. Further in vivo investigation is required to determine whether these biological effects translate into durable cartilage preservation or altered PTOA risk. Level of Evidence Laboratory study.

Yazarların özeti; kaynağından alınmıştır. Cartilage, 2026 · DOI ↗

ÇıkarımlarPremium
Makaleye SorÜcretsiz hesapla

Ücretsiz hesapla devam et

Makaleye Sor ile bu makaleye günde 3 soru ücretsiz; makaleyi kaydet, kaynakçasını al, ilgi alanına göre her gün yeni özetler. Çıkarımlar Premium.

Web'de ücretsiz devam et

Google ya da Apple hesabınla giriş; kart istemez. Bu makaleye geri dönersin.

Telefonda:

Alan: Romatoloji

RheumatologyMedicine